DALLAS, June 24, 2011 (GLOBE NEWSWIRE) -- MicroStockProfit.com announces a stock report featuring GTx Inc. (Nasdaq:GTXI). The report briefly notes the company's most recent developments and news, and outlines its financial position, market performance, and comparison against industry peers.
The full report is available at: www.microstockprofit.com/lp/GTXI
GTx Inc. (GTXI), a biopharmaceutical company, engages in the discovery, development and commercialization of small molecules that selectively target hormone pathways for the treatment of cancer and the side effects of anticancer therapy, cancer supportive care and other serious medical conditions. The Company's newest product candidate is Capesaris (GTx-758), for first line treatment of advanced prostate cancer. It is also developing Ostarine (GTx-024) and other selective androgen receptor modulators (SARMs) for the prevention and treatment of muscle loss in patients with cancer and for other muscle wasting diseases. Additionally, GTXI is developing toremifene 80 mg for the reduction of fractures and treatment of other estrogen deficiency side effects of androgen deprivation therapy for prostate cancer.
This newsletter has been helping traders make great investment decisions on GTXI; click here for a 25% discount offer.
In the report, the analyst notes:
"GTXI saw its shares plummet yesterday after it announced the pricing of its previously announced public offering of its common stock. The cancer drug developer said it intends to sell 10 million shares at $4.75 a share, a 9.2% discount to the stock's closing price of $5.23 on Wednesday."
"Shares were boosted early in the week after the Memphis, Tenn.-based company announced the initiation of a phase IIb clinical trial evaluating its oral Capesaris tablets."
To read the entire report visit: www.microstockprofit.com/lp/GTXI
See what investors are saying about GTXI at http://www.stockhideout.com
Get breaking news on GTXI at http://thestockmarketwatch.com/
MicroStockProfit.com is a small-cap research and investment commentary provider. MicroStockProfit.com strives to provide a balanced view of many promising small-cap companies that would otherwise fall under the radar of the typical Wall Street investor. We provide investors with an excellent first step in their research and due diligence by providing daily trading ideas, and consolidating the public information available on them. For more information on MicroStockProfit please visit: http://www.microstockprofit.com
MicroStockProfit.com Disclosure
MicroStockProfit.com is not a registered investment advisor and nothing contained in any materials should be construed as a recommendation to buy or sell any securities. MicroStockProfit.com is a Web site wholly owned by BlueWave Advisors, LLC. Neither MicroStockProfit.com nor its affiliates have a beneficial interest in the mentioned company; nor have they received compensation of any kind for any of the companies listed in this communication. Please read our report and visit our Web site, MicroStockProfit.com, for complete risks and disclosures.